冻融移植周期应用来曲唑促排是否改善妊娠率?

2024-02-25 生殖医学论坛 生殖医学论坛 发表于上海

本研究的目的是比较在排卵正常的不孕女性中自然FET(nat-FET)与来曲唑FET(let-FET)周期的妊娠率。

OBJECTIVE

目的

Prior studies have shown higher pregnancy rates with FET following letrozole induced ovulation compared to those following natural ovulation. The aim of this study was to compare the pregnancy rates of natural (nat-FET) vs letrozole FET (let-FET) cycles in infertile women that were ovulatory.

既往研究提示来曲唑诱导排卵后,冷冻胚胎移植(FET)的妊娠率较自然排卵后的妊娠率更高。本研究的目的是比较在排卵正常的不孕女性中自然FET(nat-FET)与来曲唑FET(let-FET)周期的妊娠率。

MATERIALS AND METHODS

材料与方法

Retrospective cohort study performed in a university-affiliated fertility practice. All natural and letrozole FET cycles from 2015 to 2022 were included. Primary outcome was ongoing pregnancy rate (OPR). Secondary outcomes included rates of pregnancy (PR), biochemical loss, clinical pregnancy (CPR), clinical loss, and ectopic pregnancy. Continuous variables were compared using Student’s t-test. Categorical variables were compared with Chi-square or Fisher’s exact test. The outcomes were adjusted for BMI and age at embryo cryopreservation with multivariate logistic regression. A subgroup analysis including only PGT-A cycles was also performed.

 

回顾性队列研究在一家大学附属生育机构完成。纳入了所有2015年至2022年间自然周期及来曲唑诱导排卵冻融胚胎移植周期。首要结局是持续妊娠率(OPR),次要结局包括妊娠率(PR)、生化妊娠丢失、临床妊娠率(CPR),流产率以及异位妊娠率。连续变量应用T检验,分类变量应用卡方检验或Fisher正确概率检验。采用多变量逻辑回归对BMI和冻存胚胎时年龄进行调整。还进行了仅包括PGT-A周期的亚组分析。

RESULTS

结局

A total of 2466 FET cycles were included, with 1907 natural (77%) and 559 (23%) letrozole cycles. Patients who underwent letrozole FET had a higher BMI (27.7 vs 26.3 kg/m2, p < .01) and were younger at embryo transfer (35.5 vs 35.9 years, p = .047) and embryo cryopreservation (35.0 vs 35.4 years, p = .042). The rates of PGT-A (37 vs 35%, p = 0.25) were similar between groups. OPRs were similar between groups as well as the PR, CPR, biochemical loss rate, clinical pregnancy loss rate, and ectopic pregnancy rate (table 1). The pregnancy rates remained similar between groups after adjusting for BMI and age at embryo cryopreservation using multivariate logistic regression. Among the 867 FET cycles that utilized PGT-A, OPRs were similar between groups despite a higher clinical loss rate in the letrozole group (table 1). The other pregnancy rates were similar between groups. The results were unchanged after adjusting for BMI and age at embryo cryopreservation.

共计纳入2466周期,其中自然周期1907例(77%),LE诱导周期559例(23%)。应用来曲唑的冻融周期患者的BMI更高 (27.7 vs 26.3 kg/m2, p <0.01),且胚胎移植(35.5岁vs 35.9岁, p=0.047)及冻存时更年轻(35.0岁vs 35.4岁, p=0.042)。PGT-A率在组间类似(37 vs 35%,p=0.25)。持续妊娠率(OPRs)与临床妊娠率(PR)、妊娠率(CPR)及生化妊娠、临床妊娠丢失率以及异位妊娠率之间无显著差异。采用多变量逻辑回归经对BMI和冻存胚胎年龄校正后妊娠率无差异。应用PGT-A的867周期中,尽管来曲唑组有更高的临床妊娠丢失率,持续妊娠率(OPRs)相近。其他妊娠率组间亦类似。结果经由BMI及冻存胚胎时年龄校正后亦无改变。

CONCLUSIONS

结论

Among ovulatory women, the use of letrozole to stimulate ovulation was not associated with improved pregnancy rates.

排卵功能正常的女性中应用来曲唑诱导排卵并不能提高妊娠率。

IMPACT STATEMENT

影响陈述

This is the first study we are aware of that compared the pregnancy outcomes of natural FET to letrozole stimulated FET in women who are ovulatory. Our study suggests that letrozole might not improve pregnancy rates compared to natural FET cycles in ovulatory women.

这是我们所知首个针对可自发排卵女性应用来曲唑诱导排卵与自然冻融胚胎周期妊娠结局比较的研究。我们的研究提示在可自发排卵的女性中来曲唑的应用可能并不提高冻融胚胎周期妊娠率。

文章来源:

DOES STIMULATING OVULATION WITH LETROZOLE DURING FROZEN EMBRYO TRANSFER (FET) CYCLES IMPROVE PREGNANCY RATES IN OVULATORY WOMEN?Wai Cheung, Jessica Ka et al.Fertility and Sterility, Volume 120, Issue 4, e304

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (2)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2189231, encodeId=9ce32189231be, content=已经学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sun Feb 25 09:49:46 CST 2024, time=2024-02-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2188592, encodeId=0e952188592d1, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a> <a href='/topic/show?id=c8913113438' target=_blank style='color:#2F92EE;'>#冷冻胚胎移植#</a> <a href='/topic/show?id=358a111389e5' target=_blank style='color:#2F92EE;'>#冻融移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31134, encryptionId=c8913113438, topicName=冷冻胚胎移植), TopicDto(id=111389, encryptionId=358a111389e5, topicName=冻融移植), TopicDto(id=61557, encryptionId=b02b6155ec9, topicName=来曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Wed Feb 21 23:35:49 CST 2024, time=2024-02-21, status=1, ipAttribution=上海)]
    2024-02-25 phoebeyan520 来自广东省

    已经学习,谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2189231, encodeId=9ce32189231be, content=已经学习,谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1bb241978, createdName=phoebeyan520, createdTime=Sun Feb 25 09:49:46 CST 2024, time=2024-02-25, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2188592, encodeId=0e952188592d1, content=<a href='/topic/show?id=b02b6155ec9' target=_blank style='color:#2F92EE;'>#来曲唑#</a> <a href='/topic/show?id=c8913113438' target=_blank style='color:#2F92EE;'>#冷冻胚胎移植#</a> <a href='/topic/show?id=358a111389e5' target=_blank style='color:#2F92EE;'>#冻融移植#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31134, encryptionId=c8913113438, topicName=冷冻胚胎移植), TopicDto(id=111389, encryptionId=358a111389e5, topicName=冻融移植), TopicDto(id=61557, encryptionId=b02b6155ec9, topicName=来曲唑)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cade5395722, createdName=梅斯管理员, createdTime=Wed Feb 21 23:35:49 CST 2024, time=2024-02-21, status=1, ipAttribution=上海)]

相关资讯

NEJM:瑞博西尼加来曲唑治疗晚期乳腺癌的总体生存率

在HR阳性、HER2阴性晚期乳腺癌患者中,与安慰剂加来曲唑相比,瑞博西尼加来曲唑的一线治疗能具有显著的总体生存获益。瑞博西尼的中位总生存期比安慰剂长12个月以上。

克罗米芬、来曲唑促排特点,常见问题及对策!很详细!

克罗米芬(CC)和来曲唑(LE)是门诊常用促排卵药物。那么这两种药物怎么用?有哪些特点?又会遇到哪些问题?本文进行了总结,供大家参考交流。

Fertility and Sterility:卵泡大小与雌二醇水平:扳机是否过早?

该研究旨在探讨卵泡大小与雌二醇水平对扳机的影响。

JCO :OS无显著差异!帕布昔利布(palbociclib)联合来曲唑治疗晚期乳腺癌的总体生存率分析

该研究报告了帕布昔利布(palbociclib)联合来曲唑治疗晚期乳腺癌的总体生存率分析,帕布昔利布联合来曲唑组与安慰剂联合来曲唑组相比,能够显著延长患者的无进展生存期,两组的总体生存期无显著差异。

Lancet Oncol:来曲唑延长治疗5年可显著提高已绝经的早期乳腺癌患者的生存预后

来曲唑延长治疗5年可相比来曲唑标准治疗2-3年显著提高既往接受过他莫西芬治疗2-3年的已绝经的乳腺癌患者的无病生存率

Eur J Cancer:来曲唑+帕博西尼新辅助治疗或可替代高危型ER+HER2-乳腺癌的化疗

来曲唑+帕博西尼新辅助治疗或可替代高危型雌激素受体阳性HER2阴性的乳腺癌女性患者的化疗。

J Clin Oncol:来曲唑联合阿贝西利治疗复发性ER阳性子宫内膜癌

来曲唑联合阿贝西利在复发性ER阳性子宫内膜癌患者中展现出了令人鼓舞的持续的治疗活性

Lancet子刊:好消息!徐兵河团队发现激素受体阳性、HER2阴性晚期乳腺癌新的潜在一线治疗方法

该研究结果表明,达尔西利联合来曲唑或阿那曲唑可能是激素受体阳性、HER2阴性晚期乳腺癌患者的一种新的标准一线治疗方法,是目前治疗方案的另一种选择。

Lancet Oncol:Dalpiciclib联合来曲唑或阿那曲唑一线治疗激素受体阳性、HER阴性晚期乳腺癌

Dalpiciclib联合来曲唑或阿那曲唑可能是激素受体阳性、HER2阴性晚期乳腺癌的一种新的标准一线治疗方法

曲唑联合地塞米松,可增加来曲唑抵抗PCOS 患者排卵率?

评估地塞米松联合来曲唑在来曲唑抵抗的PCOS中诱导排卵的疗效。